Biomm

Biomm EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Biomm (BIOM3.SA) as of Nov 9, 2026 is 184.92. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -10.06 — a change of -1,938.66% (higher).

EV/EBITDA

184.92

YoY

-1,938.66%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Biomm is 2025 184.92 . EV/EBITDA (Enterprise Value to EBITDA) of Biomm was 2024 -10.06 . It decreases by -1,938.66% higher compared to the previous year.

The Biomm EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-28.17 BRL
Jan 1, 2019
-18.85 BRL
Jan 1, 2020
-14.90 BRL
Jan 1, 2021
-14.80 BRL
Jan 1, 2022
-10.71 BRL
Jan 1, 2023
-12.96 BRL
Jan 1, 2024
-10.06 BRL
Jan 1, 2025
184.92 BRL
The Biomm EV/EBITDA history
YEAREV/EBITDAYoY
184.92-1,938.66%
-10.06-22.40%
-12.96+21.04%
-10.71-27.66%
-14.80-0.68%
-14.90-20.92%
-18.85-33.10%
-28.17-5.57%
-29.84+40.12%
-21.29-42.20%
-36.84-22.10%
-47.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

EV/EBITDA (Enterprise Value to EBITDA) of Biomm is 184.92 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Biomm changed from -10.06 to 184.92, representing a -1,938.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Biomm since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Biomm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomm

All Key Metrics — Biomm